ArticleClinical case reports2019

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.

Ritsuko Nakai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.